nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrimeprazine—CYP1A2—Clobetasol propionate—psoriasis	0.242	0.35	CbGbCtD
Methotrimeprazine—CYP1A2—Methoxsalen—psoriasis	0.127	0.184	CbGbCtD
Methotrimeprazine—CYP2D6—Hydroxyurea—psoriasis	0.115	0.166	CbGbCtD
Methotrimeprazine—CYP2D6—Cholecalciferol—psoriasis	0.0695	0.1	CbGbCtD
Methotrimeprazine—CYP2E1—Dexamethasone—psoriasis	0.0631	0.0911	CbGbCtD
Methotrimeprazine—CYP2D6—Cyclosporine—psoriasis	0.0456	0.0659	CbGbCtD
Methotrimeprazine—CYP2D6—Dexamethasone—psoriasis	0.0301	0.0434	CbGbCtD
Methotrimeprazine—Photosensitivity reaction—Tazarotene—psoriasis	0.00537	0.0484	CcSEcCtD
Methotrimeprazine—Photosensitivity—Acitretin—psoriasis	0.00371	0.0334	CcSEcCtD
Methotrimeprazine—Liver injury—Mycophenolic acid—psoriasis	0.00351	0.0316	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Calcipotriol—psoriasis	0.00335	0.0301	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Methoxsalen—psoriasis	0.00324	0.0292	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Mycophenolic acid—psoriasis	0.00295	0.0266	CcSEcCtD
Methotrimeprazine—Liver injury—Cyclosporine—psoriasis	0.00284	0.0255	CcSEcCtD
Methotrimeprazine—Drowsiness—Calcitriol—psoriasis	0.00282	0.0254	CcSEcCtD
Methotrimeprazine—Liver injury—Mycophenolate mofetil—psoriasis	0.00277	0.0249	CcSEcCtD
Methotrimeprazine—Sudden death—Methotrexate—psoriasis	0.00258	0.0232	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Acitretin—psoriasis	0.00257	0.0231	CcSEcCtD
Methotrimeprazine—Weight increased—Acitretin—psoriasis	0.00256	0.0231	CcSEcCtD
Methotrimeprazine—Jaundice—Acitretin—psoriasis	0.00245	0.022	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Cyclosporine—psoriasis	0.00239	0.0215	CcSEcCtD
Methotrimeprazine—Hepatocellular injury—Mycophenolate mofetil—psoriasis	0.00233	0.021	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Clobetasol propionate—psoriasis	0.00209	0.0188	CcSEcCtD
Methotrimeprazine—Urinary retention—Mycophenolic acid—psoriasis	0.00204	0.0183	CcSEcCtD
Methotrimeprazine—Weight increased—Hydroxyurea—psoriasis	0.00201	0.0181	CcSEcCtD
Methotrimeprazine—Drowsiness—Hydroxyurea—psoriasis	0.00197	0.0177	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Mycophenolic acid—psoriasis	0.00196	0.0176	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Fluocinonide—psoriasis	0.00189	0.017	CcSEcCtD
Methotrimeprazine—Weight increased—Mycophenolic acid—psoriasis	0.00169	0.0152	CcSEcCtD
Methotrimeprazine—Jaundice—Mycophenolic acid—psoriasis	0.00161	0.0145	CcSEcCtD
Methotrimeprazine—Urinary retention—Mycophenolate mofetil—psoriasis	0.00161	0.0145	CcSEcCtD
Methotrimeprazine—Somnolence—Calcitriol—psoriasis	0.0016	0.0144	CcSEcCtD
Methotrimeprazine—Orthostatic hypotension—Mycophenolate mofetil—psoriasis	0.00154	0.0139	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Mycophenolic acid—psoriasis	0.00154	0.0139	CcSEcCtD
Methotrimeprazine—Constipation—Calcitriol—psoriasis	0.00154	0.0139	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Methoxsalen—psoriasis	0.00149	0.0134	CcSEcCtD
Methotrimeprazine—Somnolence—Acitretin—psoriasis	0.00142	0.0128	CcSEcCtD
Methotrimeprazine—Constipation—Acitretin—psoriasis	0.00137	0.0123	CcSEcCtD
Methotrimeprazine—Weight increased—Cyclosporine—psoriasis	0.00136	0.0123	CcSEcCtD
Methotrimeprazine—Weight increased—Mycophenolate mofetil—psoriasis	0.00133	0.012	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Calcitriol—psoriasis	0.00133	0.0119	CcSEcCtD
Methotrimeprazine—Jaundice—Cyclosporine—psoriasis	0.0013	0.0117	CcSEcCtD
Methotrimeprazine—Jaundice—Mycophenolate mofetil—psoriasis	0.00127	0.0114	CcSEcCtD
Methotrimeprazine—Weight increased—Prednisolone—psoriasis	0.00124	0.0112	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Mycophenolate mofetil—psoriasis	0.00122	0.0109	CcSEcCtD
Methotrimeprazine—Weight increased—Hydrocortisone—psoriasis	0.00121	0.0109	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Acitretin—psoriasis	0.00118	0.0106	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Fluocinolone Acetonide—psoriasis	0.00118	0.0106	CcSEcCtD
Methotrimeprazine—Weight increased—Triamcinolone—psoriasis	0.00114	0.0103	CcSEcCtD
Methotrimeprazine—Somnolence—Hydroxyurea—psoriasis	0.00112	0.0101	CcSEcCtD
Methotrimeprazine—Photosensitivity—Methotrexate—psoriasis	0.00109	0.00982	CcSEcCtD
Methotrimeprazine—Constipation—Hydroxyurea—psoriasis	0.00108	0.00968	CcSEcCtD
Methotrimeprazine—Weight increased—Betamethasone—psoriasis	0.00104	0.00932	CcSEcCtD
Methotrimeprazine—Weight increased—Dexamethasone—psoriasis	0.00104	0.00932	CcSEcCtD
Methotrimeprazine—Tachycardia—Mycophenolic acid—psoriasis	0.00103	0.00925	CcSEcCtD
Methotrimeprazine—Somnolence—Mycophenolic acid—psoriasis	0.000936	0.00843	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Hydroxyurea—psoriasis	0.000927	0.00834	CcSEcCtD
Methotrimeprazine—Weight increased—Prednisone—psoriasis	0.000902	0.00812	CcSEcCtD
Methotrimeprazine—Constipation—Mycophenolic acid—psoriasis	0.000901	0.00811	CcSEcCtD
Methotrimeprazine—Tachycardia—Mycophenolate mofetil—psoriasis	0.000811	0.0073	CcSEcCtD
Methotrimeprazine—Somnolence—Cyclosporine—psoriasis	0.000758	0.00682	CcSEcCtD
Methotrimeprazine—Tachycardia—Prednisolone—psoriasis	0.000757	0.00681	CcSEcCtD
Methotrimeprazine—Photosensitivity reaction—Methotrexate—psoriasis	0.000756	0.0068	CcSEcCtD
Methotrimeprazine—Tachycardia—Hydrocortisone—psoriasis	0.000739	0.00665	CcSEcCtD
Methotrimeprazine—Somnolence—Mycophenolate mofetil—psoriasis	0.000739	0.00665	CcSEcCtD
Methotrimeprazine—Drowsiness—Methotrexate—psoriasis	0.000738	0.00664	CcSEcCtD
Methotrimeprazine—Constipation—Cyclosporine—psoriasis	0.000729	0.00656	CcSEcCtD
Methotrimeprazine—Constipation—Mycophenolate mofetil—psoriasis	0.000711	0.0064	CcSEcCtD
Methotrimeprazine—Tachycardia—Triamcinolone—psoriasis	0.000696	0.00626	CcSEcCtD
Methotrimeprazine—Agranulocytosis—Methotrexate—psoriasis	0.000689	0.0062	CcSEcCtD
Methotrimeprazine—Tachycardia—Dexamethasone—psoriasis	0.000632	0.00568	CcSEcCtD
Methotrimeprazine—Tachycardia—Betamethasone—psoriasis	0.000632	0.00568	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Cyclosporine—psoriasis	0.000628	0.00565	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000612	0.00551	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Prednisolone—psoriasis	0.000571	0.00514	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Hydrocortisone—psoriasis	0.000558	0.00502	CcSEcCtD
Methotrimeprazine—Tachycardia—Prednisone—psoriasis	0.00055	0.00495	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Triamcinolone—psoriasis	0.000525	0.00473	CcSEcCtD
Methotrimeprazine—Constipation—Prednisone—psoriasis	0.000482	0.00434	CcSEcCtD
Methotrimeprazine—Somnolence—Methotrexate—psoriasis	0.000419	0.00377	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Prednisone—psoriasis	0.000415	0.00374	CcSEcCtD
Methotrimeprazine—Hypersensitivity—Methotrexate—psoriasis	0.000347	0.00312	CcSEcCtD
Methotrimeprazine—HRH1—Signaling by GPCR—TYK2—psoriasis	4.51e-05	0.00023	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—CAT—psoriasis	4.5e-05	0.000229	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—TYK2—psoriasis	4.5e-05	0.000229	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—TYK2—psoriasis	4.48e-05	0.000228	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling by GPCR—IL6—psoriasis	4.48e-05	0.000228	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—TYK2—psoriasis	4.44e-05	0.000226	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—TYK2—psoriasis	4.43e-05	0.000226	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling by GPCR—CXCL8—psoriasis	4.41e-05	0.000225	CbGpPWpGaD
Methotrimeprazine—DRD2—GPCR downstream signaling—CXCL8—psoriasis	4.41e-05	0.000224	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—CARM1—psoriasis	4.4e-05	0.000224	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—NFKBIA—psoriasis	4.39e-05	0.000224	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—JUN—psoriasis	4.38e-05	0.000223	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling by GPCR—CXCL8—psoriasis	4.34e-05	0.000221	CbGpPWpGaD
Methotrimeprazine—HTR2A—GPCR downstream signaling—CXCL8—psoriasis	4.34e-05	0.000221	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—NFKBIA—psoriasis	4.33e-05	0.000221	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—NFKBIA—psoriasis	4.33e-05	0.000221	CbGpPWpGaD
Methotrimeprazine—HRH1—GPCR downstream signaling—CXCL8—psoriasis	4.33e-05	0.00022	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—SOCS1—psoriasis	4.31e-05	0.00022	CbGpPWpGaD
Methotrimeprazine—CHRM1—GPCR downstream signaling—CXCL8—psoriasis	4.31e-05	0.00022	CbGpPWpGaD
Methotrimeprazine—CHRM3—GPCR downstream signaling—CXCL8—psoriasis	4.3e-05	0.000219	CbGpPWpGaD
Methotrimeprazine—CHRM2—GPCR downstream signaling—CXCL8—psoriasis	4.26e-05	0.000217	CbGpPWpGaD
Methotrimeprazine—ADRA1A—GPCR downstream signaling—CXCL8—psoriasis	4.25e-05	0.000216	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—NFKB1—psoriasis	4.22e-05	0.000215	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—LEP—psoriasis	4.2e-05	0.000214	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—APOE—psoriasis	4.2e-05	0.000214	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—APOE—psoriasis	4.15e-05	0.000211	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—TYK2—psoriasis	4.11e-05	0.00021	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.11e-05	0.000209	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—PPARG—psoriasis	4.08e-05	0.000208	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—LEP—psoriasis	4.03e-05	0.000205	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—APOE—psoriasis	4.03e-05	0.000205	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—CXCL8—psoriasis	4e-05	0.000204	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—TYK2—psoriasis	3.99e-05	0.000203	CbGpPWpGaD
Methotrimeprazine—ADRA2A—GPCR downstream signaling—CXCL8—psoriasis	3.94e-05	0.000201	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—TYK2—psoriasis	3.94e-05	0.000201	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—CXCL8—psoriasis	3.94e-05	0.000201	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—CXCL8—psoriasis	3.93e-05	0.0002	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—LEP—psoriasis	3.92e-05	0.0002	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—APOE—psoriasis	3.92e-05	0.0002	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—CXCL8—psoriasis	3.92e-05	0.000199	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—NFKBIA—psoriasis	3.91e-05	0.000199	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—CXCL8—psoriasis	3.9e-05	0.000199	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—CXCL8—psoriasis	3.87e-05	0.000197	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—LEP—psoriasis	3.86e-05	0.000197	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—APOE—psoriasis	3.86e-05	0.000197	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—CXCL8—psoriasis	3.85e-05	0.000196	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Hemostasis—TP53—psoriasis	3.83e-05	0.000195	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—VEGFA—psoriasis	3.83e-05	0.000195	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—APOE—psoriasis	3.81e-05	0.000194	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—STAT3—psoriasis	3.79e-05	0.000193	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—TYK2—psoriasis	3.77e-05	0.000192	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—NFKBIA—psoriasis	3.76e-05	0.000191	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—NFKBIA—psoriasis	3.65e-05	0.000186	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—PPARG—psoriasis	3.61e-05	0.000184	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—TYK2—psoriasis	3.6e-05	0.000183	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—NFKBIA—psoriasis	3.6e-05	0.000183	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—CXCL8—psoriasis	3.58e-05	0.000182	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—LEP—psoriasis	3.56e-05	0.000181	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—APOE—psoriasis	3.56e-05	0.000181	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—TYK2—psoriasis	3.55e-05	0.000181	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—TYK2—psoriasis	3.55e-05	0.000181	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—APOE—psoriasis	3.5e-05	0.000178	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—LEP—psoriasis	3.5e-05	0.000178	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—APOE—psoriasis	3.5e-05	0.000178	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—APOE—psoriasis	3.49e-05	0.000178	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—LEP—psoriasis	3.49e-05	0.000178	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—LEP—psoriasis	3.48e-05	0.000177	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—APOE—psoriasis	3.48e-05	0.000177	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—CXCL8—psoriasis	3.48e-05	0.000177	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—APOE—psoriasis	3.47e-05	0.000177	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—LEP—psoriasis	3.47e-05	0.000177	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—LEP—psoriasis	3.44e-05	0.000175	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—APOE—psoriasis	3.44e-05	0.000175	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—CXCL8—psoriasis	3.43e-05	0.000175	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—APOE—psoriasis	3.43e-05	0.000175	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—LEP—psoriasis	3.43e-05	0.000175	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—PPARG—psoriasis	3.32e-05	0.000169	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—NFKBIA—psoriasis	3.31e-05	0.000169	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling by GPCR—IL6—psoriasis	3.31e-05	0.000168	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—CXCL8—psoriasis	3.29e-05	0.000167	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling by GPCR—IL6—psoriasis	3.26e-05	0.000166	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—NFKBIA—psoriasis	3.26e-05	0.000166	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—NFKBIA—psoriasis	3.25e-05	0.000166	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—NFKBIA—psoriasis	3.24e-05	0.000165	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—NFKBIA—psoriasis	3.23e-05	0.000165	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—JUN—psoriasis	3.23e-05	0.000165	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—TYK2—psoriasis	3.2e-05	0.000163	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—NFKBIA—psoriasis	3.2e-05	0.000163	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—CAT—psoriasis	3.19e-05	0.000163	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—NFKBIA—psoriasis	3.19e-05	0.000163	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—JUN—psoriasis	3.19e-05	0.000162	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—LEP—psoriasis	3.18e-05	0.000162	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—APOE—psoriasis	3.18e-05	0.000162	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—CXCL8—psoriasis	3.13e-05	0.000159	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling by GPCR—IL6—psoriasis	3.12e-05	0.000159	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—NFKB1—psoriasis	3.11e-05	0.000159	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—CXCL8—psoriasis	3.09e-05	0.000157	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—CXCL8—psoriasis	3.09e-05	0.000157	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—TYK2—psoriasis	3.08e-05	0.000157	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—NFKB1—psoriasis	3.07e-05	0.000156	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—JUN—psoriasis	3.05e-05	0.000156	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—PPARG—psoriasis	3.05e-05	0.000155	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—TYK2—psoriasis	2.99e-05	0.000152	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling by GPCR—IL6—psoriasis	2.98e-05	0.000152	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—NFKBIA—psoriasis	2.97e-05	0.000151	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—TYK2—psoriasis	2.94e-05	0.00015	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—NFKB1—psoriasis	2.94e-05	0.00015	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling by GPCR—IL6—psoriasis	2.94e-05	0.00015	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling by GPCR—IL6—psoriasis	2.94e-05	0.00015	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—JUN—psoriasis	2.91e-05	0.000148	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—TP53—psoriasis	2.89e-05	0.000147	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—JUN—psoriasis	2.87e-05	0.000146	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—JUN—psoriasis	2.87e-05	0.000146	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—VEGFA—psoriasis	2.82e-05	0.000144	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—NFKB1—psoriasis	2.8e-05	0.000143	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—STAT3—psoriasis	2.8e-05	0.000142	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—CXCL8—psoriasis	2.79e-05	0.000142	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—VEGFA—psoriasis	2.79e-05	0.000142	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—NFKB1—psoriasis	2.76e-05	0.000141	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—NFKB1—psoriasis	2.76e-05	0.000141	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—STAT3—psoriasis	2.76e-05	0.000141	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—TYK2—psoriasis	2.71e-05	0.000138	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—CAT—psoriasis	2.71e-05	0.000138	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—CXCL8—psoriasis	2.68e-05	0.000136	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—TYK2—psoriasis	2.67e-05	0.000136	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—VEGFA—psoriasis	2.67e-05	0.000136	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—TYK2—psoriasis	2.67e-05	0.000136	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—TYK2—psoriasis	2.66e-05	0.000135	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling by GPCR—IL6—psoriasis	2.65e-05	0.000135	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—TYK2—psoriasis	2.65e-05	0.000135	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—IL6—psoriasis	2.65e-05	0.000135	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—STAT3—psoriasis	2.64e-05	0.000135	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—TYK2—psoriasis	2.62e-05	0.000134	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—TYK2—psoriasis	2.62e-05	0.000133	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—CXCL8—psoriasis	2.6e-05	0.000133	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—JUN—psoriasis	2.59e-05	0.000132	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—CXCL8—psoriasis	2.56e-05	0.000131	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling by GPCR—IL6—psoriasis	2.55e-05	0.00013	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—VEGFA—psoriasis	2.54e-05	0.00013	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—STAT3—psoriasis	2.52e-05	0.000128	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—VEGFA—psoriasis	2.51e-05	0.000128	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—VEGFA—psoriasis	2.51e-05	0.000128	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—NFKB1—psoriasis	2.5e-05	0.000127	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—JUN—psoriasis	2.49e-05	0.000127	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—STAT3—psoriasis	2.48e-05	0.000127	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—STAT3—psoriasis	2.48e-05	0.000127	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—APOE—psoriasis	2.48e-05	0.000126	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling by GPCR—IL6—psoriasis	2.48e-05	0.000126	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling by GPCR—IL6—psoriasis	2.44e-05	0.000124	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—TYK2—psoriasis	2.43e-05	0.000124	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—JUN—psoriasis	2.42e-05	0.000123	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—NFKB1—psoriasis	2.4e-05	0.000122	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—JUN—psoriasis	2.38e-05	0.000121	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—CXCL8—psoriasis	2.36e-05	0.00012	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—NFKB1—psoriasis	2.33e-05	0.000119	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—CXCL8—psoriasis	2.33e-05	0.000118	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—CXCL8—psoriasis	2.32e-05	0.000118	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—CXCL8—psoriasis	2.31e-05	0.000118	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—CXCL8—psoriasis	2.31e-05	0.000117	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—NFKB1—psoriasis	2.29e-05	0.000117	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CXCL8—psoriasis	2.28e-05	0.000116	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CXCL8—psoriasis	2.28e-05	0.000116	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—VEGFA—psoriasis	2.27e-05	0.000115	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—IL6—psoriasis	2.25e-05	0.000114	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—STAT3—psoriasis	2.24e-05	0.000114	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—IL6—psoriasis	2.21e-05	0.000113	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—IL6—psoriasis	2.21e-05	0.000112	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—IL6—psoriasis	2.2e-05	0.000112	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—JUN—psoriasis	2.2e-05	0.000112	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—IL6—psoriasis	2.19e-05	0.000112	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—VEGFA—psoriasis	2.18e-05	0.000111	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—IL6—psoriasis	2.17e-05	0.000111	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—IL6—psoriasis	2.17e-05	0.00011	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—JUN—psoriasis	2.16e-05	0.00011	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—PPARG—psoriasis	2.16e-05	0.00011	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—JUN—psoriasis	2.16e-05	0.00011	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—STAT3—psoriasis	2.15e-05	0.00011	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—JUN—psoriasis	2.15e-05	0.00011	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—JUN—psoriasis	2.14e-05	0.000109	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—TP53—psoriasis	2.13e-05	0.000109	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—JUN—psoriasis	2.12e-05	0.000108	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—JUN—psoriasis	2.12e-05	0.000108	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CXCL8—psoriasis	2.12e-05	0.000108	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—VEGFA—psoriasis	2.12e-05	0.000108	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—NFKB1—psoriasis	2.12e-05	0.000108	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—TP53—psoriasis	2.11e-05	0.000107	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—APOE—psoriasis	2.1e-05	0.000107	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—STAT3—psoriasis	2.09e-05	0.000107	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—VEGFA—psoriasis	2.08e-05	0.000106	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—NFKB1—psoriasis	2.08e-05	0.000106	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—NFKB1—psoriasis	2.08e-05	0.000106	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—NFKB1—psoriasis	2.07e-05	0.000105	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—NFKB1—psoriasis	2.06e-05	0.000105	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—STAT3—psoriasis	2.06e-05	0.000105	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—NFKB1—psoriasis	2.04e-05	0.000104	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—NFKB1—psoriasis	2.04e-05	0.000104	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—TP53—psoriasis	2.02e-05	0.000103	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—IL6—psoriasis	2.01e-05	0.000102	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—JUN—psoriasis	1.97e-05	0.0001	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—IL6—psoriasis	1.95e-05	9.95e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—IL6—psoriasis	1.93e-05	9.82e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—TP53—psoriasis	1.92e-05	9.79e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—VEGFA—psoriasis	1.92e-05	9.78e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—STAT3—psoriasis	1.9e-05	9.68e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—TP53—psoriasis	1.9e-05	9.66e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—TP53—psoriasis	1.9e-05	9.66e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—NFKB1—psoriasis	1.89e-05	9.65e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—VEGFA—psoriasis	1.89e-05	9.62e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—VEGFA—psoriasis	1.88e-05	9.6e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—VEGFA—psoriasis	1.88e-05	9.57e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—VEGFA—psoriasis	1.87e-05	9.54e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—STAT3—psoriasis	1.87e-05	9.53e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—STAT3—psoriasis	1.87e-05	9.51e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—STAT3—psoriasis	1.86e-05	9.48e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—VEGFA—psoriasis	1.85e-05	9.45e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—STAT3—psoriasis	1.85e-05	9.45e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—VEGFA—psoriasis	1.85e-05	9.42e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—IL6—psoriasis	1.85e-05	9.4e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—STAT3—psoriasis	1.84e-05	9.35e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—STAT3—psoriasis	1.83e-05	9.33e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PPARG—psoriasis	1.83e-05	9.33e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—IL6—psoriasis	1.76e-05	8.96e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—IL6—psoriasis	1.74e-05	8.84e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—IL6—psoriasis	1.74e-05	8.84e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—VEGFA—psoriasis	1.72e-05	8.75e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—TP53—psoriasis	1.71e-05	8.72e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—STAT3—psoriasis	1.7e-05	8.67e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—TP53—psoriasis	1.64e-05	8.37e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—TP53—psoriasis	1.6e-05	8.14e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—TP53—psoriasis	1.57e-05	8.01e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—IL6—psoriasis	1.57e-05	7.98e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—IL6—psoriasis	1.5e-05	7.66e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—IL6—psoriasis	1.46e-05	7.45e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—TP53—psoriasis	1.45e-05	7.39e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—IL6—psoriasis	1.44e-05	7.34e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—TP53—psoriasis	1.43e-05	7.27e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—TP53—psoriasis	1.42e-05	7.25e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—TP53—psoriasis	1.42e-05	7.23e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—TP53—psoriasis	1.42e-05	7.21e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—TP53—psoriasis	1.4e-05	7.14e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—TP53—psoriasis	1.4e-05	7.12e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—IL6—psoriasis	1.33e-05	6.76e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—IL6—psoriasis	1.31e-05	6.66e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—IL6—psoriasis	1.3e-05	6.64e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—IL6—psoriasis	1.3e-05	6.62e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—TP53—psoriasis	1.3e-05	6.61e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—IL6—psoriasis	1.3e-05	6.6e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—IL6—psoriasis	1.28e-05	6.53e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—IL6—psoriasis	1.28e-05	6.52e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—IL6—psoriasis	1.19e-05	6.05e-05	CbGpPWpGaD
